Nicholas Turner, MD, PhD, consultant medical oncologist, The Royal Marsden Hospital, London, discusses the PALOMA-3 trial, which studied palbociclib combined with fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure.
Turner says the trial is focusing on women who have progressed on their first-line hormonal therapy. There are a number of options in this space, Turner says, but fulvestrant is one of the drugs that has the best data when given under 500mg/dose.
There is no evidence of any drug interaction between these two agents and there is strong data that endocrine-resistant cancers can still be sensitive to palbociclib. Because of this, Turner believes that this study will demonstrate that the combination will improve the length of time that cancer can be controlled.